Mumbai, April 18, 2019: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) for its Pithampur (Unit-3) facility. The inspection was conducted between October 8, 2018 to October 18, 2018.
Lupin’s Pithampur Unit-3 is involved in the manufacture of Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Topical Formulations for the regulated markets.
Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, “Receiving the EIR for our Pithampur Unit-3 facility is a very positive development and brings us one step closerto bringing important MDIs and DPIs to the market. We are committed to ensuring the quality, safety and efficacy of the products that we manufacture across our facilities.”
Corporate Comm India (CCI Newswire)
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…